Abstract. Although adjuvant high-dose interferon α-2b therapy significantly improves recurrence-free survival vs. observation in high-risk resected melanoma, the overall survival benefit is presently unclear. Pegylation of interferon α-2b (peginterferon α-2b) allows for a reduction in the dosing frequency with increased drug exposure. Adjuvant peginterferon α-2b therapy has also been shown to provide a significant, sustained improvement in recurrence-free survival compared with observation in patients with stage III melanoma. We report on the use of adjuvant peginterferon α-2b (3 µg/kg/ week) in clinical practice in a series of 8 patients treated at the Universitätsklinikum Essen in Germany following complete resection of primary melanoma at intermediate-and high-risk of recurrence (stage II-III). Treatment duration ranged from 2 to 29 months, with 4 patients receiving long-term therapy (≥24 months). Following treatment, 5 patients (stage II) remained disease-free at 33, 33, 37, 39 and 43 months from the time of diagnosis. In 2 patients, peginterferon α-2b was terminated 4 and 9 months after treatment initiation due to disease progression. Once-weekly subcutaneous administration of peginterferon α-2b was convenient in all patients. In 3 patients experiencing adverse events, dose reductions led to a resolution of symptoms and enabled treatment to continue long-term. Three further patients discontinued therapy due to adverse events at 2, 8 and 27 months of therapy (persistent elevation of γ-glutamyl transpeptidase, liver transaminase elevation and urosepsis); dose modifications were not applicable in these patients. Thus, long-term adjuvant peginterferon α-2b therapy was feasible in the clinical practice setting and was generally well tolerated in these intermediate-and highrisk melanoma patients.
Introduction
High-dose interferon α-2b is the only adjuvant therapy currently FDA-approved for high-risk resected melanoma. The high-dose regimen of 20 MU/m 2 /day intravenously (i.v.) 5 days a week for 4 weeks, then 10 MU/m 2 subcutaneously (s.c.) three times per week for 48 weeks has been shown to significantly improve recurrence-free survival vs. observation (1) (2) (3) (4) (5) . The survival benefit is remains unclear, with significant effects noted vs. observation in only one trial of high-dose interferon (3) . Clinical trial data suggest that efficacy is associated not only with dose but also with the duration of therapy (1, 3, 6) . However, high-dose interferon α-2b is associated with significant toxicity and an inconvenient three-times-weekly maintenance dosing schedule.
Pegylation of interferon α-2b (peginterferon α-2b) does not affect its biological activity but results in decreased clearance and increased half-life, allowing for a reduced dosing frequency and potentially greater efficacy owing to the altered pharmacokinetic profile and increased drug exposure (7) (8) (9) . In the EORTC 18991 phase III study, peginterferon α-2b therapy at 6 µg/kg/week for 8 weeks s.c. (induction) followed by 3 µg/kg/week s.c. (maintenance) for an intended duration of 5 years provided a significant, sustained improvement in recurrence-free survival compared with observation in patients with stage III melanoma (6) . However, no improvement in survival was observed at 3.8 years of follow-up. There was evidence for a greater benefit of peginterferon α-2b therapy in stage III patients with microscopic nodal disease (N1) vs. clinically palpable lymph nodes (N2). Similar findings were observed with interferon α-2b in this patient subgroup (2) . For the primary analysis, the median treatment duration was 12 months (interquartile range 3.8-33.4).
In the 18991 study, the toxicity profile of peginterferon α-2b was acceptable for up to 5 years of therapy. The most commonly reported grade 3/4 adverse events (AEs) observed were fatigue, hepatotoxicity, pyrexia, headache, myalgia and depression (6) . The discontinuation rate due to toxicity was 31% in the peginterferon α-2b arm, and AEs most frequently associated with discontinuation were fatigue, depression, anorexia, hepatotoxicity, myalgia, headache, nausea and pyrexia. The incidence of the most common AEs was higher early in treatment and appeared to decrease with prolonged treatment.
The present study describes the use of adjuvant peginterferon α-2b (Pegintron ® ; Schering-Plough Corporation, Kenilworth, NJ, USA), following complete resection in 8 patients with primary melanoma at intermediate-and high-risk of recurrence (stage II-III) treated at the Universitätsklinikum Essen in Germany, with a focus on tolerability. As peginterferon α-2b is not currently registered for the treatment of melanoma, it was administered under compassionate use in these patients.
Patients and Results
The characteristics of the primary melanoma at diagnosis for the 8 patients are shown in Table I , along with a summary of peginterferon α-2b dose and treatment duration. Following the complete excision of the primary melanoma, standard follow-up care was a three-monthly clinical and sonographic assessment of lymph nodes for 3 years; assessment was then carried out every 6 months. The American Joint Committee on Cancer (AJCC) 2002 staging was used throughout. Informed consent was obtained from all patients before the administration of peginterferon α-2b. The dose administered to the patients participating in this study was the maintenance dose administered in the EORTC 18991 trial (3 µg/kg/week) and was prepared according to EORTC 18991 study methods, based on the subject's body weight. Peginterferon α-2b powder for injection was provided in vials (3 µg/0.5 ml) and reconstituted in 0.7 ml sterile water for injection. The volume (ml) of reconstituted solution to be withdrawn and injected was calculated according to vial size, and the required dose was based on the subject's body weight. ----------------------------------------------------------------------------------------------- 
--------------------------------------------------------------------------------------------------------

Discussion
This study described the disease course of 8 patients who received adjuvant peginterferon α-2b therapy for the treatment of resected, intermediate-and high-risk stage II (n=7) or III melanoma with regional metastases (n=1). Five patients who received peginterferon α-2b after resection of the primary tumor (stage II) remained disease-free in June 2009 (months since diagnosis: 33, 33, 37, 39 and 43). In 2 patients (J.P. and H.H.), peginterferon α-2b was terminated due to disease progression 4 and 9 months after treatment was initiated. Patient H.J. initially received high-dose, then low-dose interferon α-2b following subsequent resections of stage III melanoma, and finally peginterferon α-2b following additional resection. The treatment duration in these 8 patients ranged from 2 to 29 months, with 4 patients receiving long-term therapy (≥24 months).
The EORTC 18991 study implemented a 'dosing to tolerance' schedule, with stepwise reductions specified in the protocol to manage toxicities while maintaining good performance status, as well as aiming to achieve long-term therapy, thereby maximizing the efficacy benefits of therapy (6) . Once-weekly s.c. administration of peginterferon α-2b was convenient in our patients. In 3 patients experiencing AEs on peginterferon α-2b, dose reductions led to the resolution of symptoms and enabled treatment to continue long-term. Five further patients discontinued peginterferon α-2b due to AEs at 2, 8 and 27 months of therapy or disease progression; dose modifications were not attempted or applicable in these patients.
High-dose peginterferon α-2b has a similar toxicity profile to high-dose interferon α-2b, with similar common toxicities (hepatotoxicity, fatigue, depression and hematologic) (10) . Practical guidelines for managing interferon toxicity have been published by Hauschild et al. These guidelines focus on initial patient assessment, ongoing monitoring, aggressive management of AEs, and recognizing when dose adjustment or discontinuation is needed (10) . Patient education prior to therapy and throughout the treatment period increases awareness and recognition of possible side effects, thereby aiding in the reduction of the severity of AEs. Consequently, the likelihood that the patient will complete therapy increases (10) . Patient M.D. showed signs of autoimmune disease (Hashimoto's thyroiditis) during adjuvant peginterferon α-2b therapy. The development of autoimmune diseases such as thyroid dysfunction has been associated with greater efficacy benefits with high-dose interferon therapy (11, 12) , although this association is regarded as controversial. More recent data from an EORTC trial (18952) and the Nordic IFN trial now suggest that this correlation is only weak, if it exists at all (13) .
For the patients participating in this study, adjuvant therapy with peginterferon α-2b was feasible and generally well tolerated for intermediate-and high-risk melanoma. Our findings therefore indicate that long-term therapy can be maintained in the clinical practice setting.
